Cardiometabolic Risk Management:
A Functional and Lifestyle Approach
Thomas G. Guilliams, PhD
Insulin resistance and related metabolic disorders drive much of the current burden of cardiovascular disease, especially where Westernized lifestyle patterns are practiced. The relationship between these overlapping pathologies has resulted in the term “cardiometabolic” risk or disease. And while lifestyle behaviors are at the root of at least 75% of the risk for these diseases, most clinical interventions look past these causes for another solution, most often a pharmaceutical option.
Those advocating for change in these priorities are frustrated by this paradox, though little is likely to change if health care providers are disproportionately educated in the benefits of pharmaceuticals and invasive rescue interventions, while the evidence for lifestyle and nutrient therapies are rarely touched upon and often only in an incomplete or negative light.
Join Dr. Thomas G. Guilliams for an upcoming webinar, where he will discuss:
The gap between the epidemiological reality and the clinical reality of cardiometabolic diseases
How to leverage current laboratory assessment to predict cardiometabolic outcomes
The latest research on targeted nutrients and treatment options aimed to reduce cardiometabolic biomarkers and risk